in vivo News and Research

RSS

Nano Terra, Kadmon sign deal to license novel product candidates

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer Technology.

25 Apr 2011

Research solves challenging problem of industry-scale production of large RNA molecules

Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.

22 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Clontech releases iDimerize inducible dimerization systems

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc., the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers.

20 Apr 2011

Study demonstrates clinical effectiveness of Systagenix ADAPTIC TOUCH as a primary wound contact layer

Systagenix announced on 20 April 2011 that a recent product evaluation published in the journal Wounds UK, Vol 7, No 1, demonstrates the clinical effectiveness of ADAPTIC TOUCH® as a primary wound contact layer that addresses the needs of both patients and healthcare professionals.

20 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Periodontal ligament stem cells most efficacious among dental tissue-derived stem cells

Periodontal ligament stem cells (PDLSCs) have been found to be the most efficacious of three kinds of clinically tested dental tissue-derived stem cells, reports a study published in the current issue of Cell Transplantation (20:2), freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

12 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

Scientists identify two molecules that enable cancer spread

For many types of cancer, the original tumor itself is usually not deadly. Instead, it's the spread of a tiny subpopulation of cells from the primary tumor to other parts of the body—the process known as metastasis—that all too often kills the patient.

8 Apr 2011

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

HemoShear, LLC, is pleased to announce that it was awarded a Phase 1 Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

7 Apr 2011

FDA to discuss 2008 immunogenicity directives with European industry experts at Pharma IQ

This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's to discuss FDA directives on immunogenicity introduced in 2008.

6 Apr 2011

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

Aeterna Zentaris Inc. today announced that a poster on its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131, was presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today presented results of preclinical studies on its novel Phosphoinositide 3-kinase alpha inhibitor at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

6 Apr 2011

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

Pervasis Therapeutics, Inc. today announced preclinical data showing positive effects of PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, on controlling tumor growth and inhibiting metastases in an animal model of prostate cancer.

6 Apr 2011

UT Southwestern gynecologist receives Burroughs Wellcome Fund for premature birth study

A UT Southwestern Medical Center gynecologist is one of five researchers nationwide selected to receive a $600,000 Burroughs Wellcome Fund grant to investigate the biological mechanisms and causes of premature birth.

6 Apr 2011

Adipocytes associated with breast cancer could amplify 'aggressive' effect of tumors in obese patients

Apart from its direct effect on health (such as cardiovascular diseases and diabetes), obesity is increasingly suspected of playing a role in the prognosis of breast cancer and, in particular, its propensity to spread. However, no direct cause and effect relationship had been demonstrated until now. This breakthrough has finally been made through the collaborative work of two teams of researchers from Inserm, CNRS and the Université Paul Sabatier.

6 Apr 2011

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life-sciences research, today announced that its Caliper Discovery Alliances and Services unit has formed a research collaboration with Denver-based Catholic Health Initiatives, one of the nation's largest health systems.

6 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

Scientists effectively combine two methods used as vehicles to carry DNA into cell nuclei

Scientists at Polytechnic Institute of New York University (NYU-Poly) and at the NYU College of Dentistry have discovered a biochemical version of a principle well known among confectioners. Call it the "peanut butter and chocolate" rule: Sometimes two things work better together than alone.

5 Apr 2011

in vivo News and Research

Nano Terra, Kadmon sign deal to license novel product candidates

Research solves challenging problem of industry-scale production of large RNA molecules

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Clontech releases iDimerize inducible dimerization systems

Study demonstrates clinical effectiveness of Systagenix ADAPTIC TOUCH as a primary wound contact layer

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Periodontal ligament stem cells most efficacious among dental tissue-derived stem cells

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Scientists identify two molecules that enable cancer spread

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

FDA to discuss 2008 immunogenicity directives with European industry experts at Pharma IQ

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

UT Southwestern gynecologist receives Burroughs Wellcome Fund for premature birth study

Adipocytes associated with breast cancer could amplify 'aggressive' effect of tumors in obese patients

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

Scientists effectively combine two methods used as vehicles to carry DNA into cell nuclei

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News